ERBB2 and neoplasm: Overexpression of HER2 occurs in ~25% of all breast cancers due to amplification of the HER2 locus at 17q12 and is associated with aggressive tumor behavior and poor outcome in the absence of HER2 targeted therapy (Slamon et al., 1989; Sorlie et al., 2003).